Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial
Authors
Keywords
-
Journal
Lancet Respiratory Medicine
Volume -, Issue -, Pages -
Publisher
Elsevier BV
Online
2021-03-25
DOI
10.1016/s2213-2600(20)30532-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Combination Therapy with Oral Treprostinil for Pulmonary Arterial Hypertension: A Double-Blind, Placebo-Controlled Study
- (2019) R. James White et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- REVEAL risk scores applied to riociguat-treated patients in PATENT-2: Impact of changes in risk score on survival
- (2018) Raymond L. Benza et al. JOURNAL OF HEART AND LUNG TRANSPLANTATION
- REVEAL risk score in patients with chronic thromboembolic pulmonary hypertension receiving riociguat
- (2018) Raymond L. Benza et al. JOURNAL OF HEART AND LUNG TRANSPLANTATION
- Pulmonary Arterial Hypertension-Related Morbidity Is Prognostic for Mortality
- (2018) Vallerie V. McLaughlin et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Risk stratification and medical therapy of pulmonary arterial hypertension
- (2018) Nazzareno Galiè et al. EUROPEAN RESPIRATORY JOURNAL
- A comprehensive risk stratification at early follow-up determines prognosis in pulmonary arterial hypertension
- (2017) David Kylhammar et al. EUROPEAN HEART JOURNAL
- RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors
- (2017) Marius M. Hoeper et al. EUROPEAN RESPIRATORY JOURNAL
- Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model
- (2017) Marius M. Hoeper et al. EUROPEAN RESPIRATORY JOURNAL
- Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension
- (2017) Athénaïs Boucly et al. EUROPEAN RESPIRATORY JOURNAL
- Rationale and study design of RESPITE: An open-label, phase 3b study of riociguat in patients with pulmonary arterial hypertension who demonstrate an insufficient response to treatment with phosphodiesterase-5 inhibitors
- (2017) Marius M. Hoeper et al. RESPIRATORY MEDICINE
- Predictors of long-term outcomes in patients treated with riociguat for pulmonary arterial hypertension: data from the PATENT-2 open-label, randomised, long-term extension trial
- (2016) Hossein-Ardeschir Ghofrani et al. Lancet Respiratory Medicine
- Five-Year Outcomes of Patients Enrolled in the REVEAL Registry
- (2015) Harrison W. Farber et al. CHEST
- 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
- (2015) Nazzareno Galiè et al. EUROPEAN HEART JOURNAL
- Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2)
- (2015) Lewis J. Rubin et al. EUROPEAN RESPIRATORY JOURNAL
- 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
- (2015) Nazzareno Galiè et al. EUROPEAN RESPIRATORY JOURNAL
- Prognostic implications of serial risk score assessments in patients with pulmonary arterial hypertension: A Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL) analysis
- (2015) Raymond L. Benza et al. JOURNAL OF HEART AND LUNG TRANSPLANTATION
- Selexipag for the Treatment of Pulmonary Arterial Hypertension
- (2015) Olivier Sitbon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension
- (2015) Nazzareno Galiè et al. NEW ENGLAND JOURNAL OF MEDICINE
- Advances in Therapeutic Interventions for Patients With Pulmonary Arterial Hypertension
- (2014) Marc Humbert et al. CIRCULATION
- Macitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension
- (2013) Tomás Pulido et al. NEW ENGLAND JOURNAL OF MEDICINE
- Riociguat for the Treatment of Pulmonary Arterial Hypertension
- (2013) Hossein-Ardeschir Ghofrani et al. NEW ENGLAND JOURNAL OF MEDICINE
- An Evaluation of Long-term Survival From Time of Diagnosis in Pulmonary Arterial Hypertension From the REVEAL Registry
- (2012) Raymond L. Benza et al. CHEST
- Long-term Treatment With Sildenafil Citrate in Pulmonary Arterial Hypertension
- (2011) Lewis J. Rubin et al. CHEST
- Predicting Survival in Pulmonary Arterial Hypertension
- (2010) Raymond L. Benza et al. CIRCULATION
- Tadalafil Therapy for Pulmonary Arterial Hypertension
- (2009) Nazzareno Galiè et al. CIRCULATION
- Phosphodiesterase Type 5 Inhibitors for Pulmonary Arterial Hypertension
- (2009) Stephen L. Archer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cyclic GMP signaling in cardiovascular pathophysiology and therapeutics
- (2009) Emily J. Tsai et al. PHARMACOLOGY & THERAPEUTICS
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started